Keryx Biopharmaceuticals Inc (KERX.OQ)
KERX.OQ on NASDAQ Stock Exchange Capital Market
9.23USD
1 Aug 2013
9.23USD
1 Aug 2013
Price Change (% chg)
$0.13 (+1.43%)
$0.13 (+1.43%)
Prev Close
$9.10
$9.10
Open
$9.20
$9.20
Day's High
$9.28
$9.28
Day's Low
$9.14
$9.14
Volume
39,554
39,554
Avg. Vol
554,251
554,251
52-wk High
$9.98
$9.98
52-wk Low
$1.68
$1.68
About
Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. The Company is developing KRX-0401, an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase... (more)
Overall
| Beta: | 3.88 |
| Market Cap (Mil.): | $743.63 |
| Shares Outstanding (Mil.): | 81.72 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| KERX.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 47.13 | 37.76 |
| EPS (TTM): | -0.25 | -- | -- |
| ROI: | -33.54 | -2.58 | 18.76 |
| ROE: | -34.38 | -2.66 | 19.59 |
Competitors
| Price | Change | |
|---|---|---|
| Takeda Pharmaceutical Company Limited (4502.T) | ¥4,580 | +205.00 |
| Astellas Pharma Inc (4503.T) | ¥5,340 | +90.00 |
| Pfizer Inc. (PFE.N) | $29.29 | +0.06 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Merck & Co., Inc. (MRK.N) | $48.34 | +0.17 |
| Bayer AG (BAYGn.DE) | €89.64 | +2.29 |
| Bayer AG (BAYE.F) | -- | -- |
| Sanofi SA (SASY.PA) | €76.89 | -3.28 |
| Eli Lilly & Co. (LLY.N) | $53.29 | +0.18 |
| Amgen, Inc. (AMGN.OQ) | $108.86 | +0.57 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

